N.I. BEYLINA, A.O. POZDNYAK, S.F. SUBKHANKULOVA

 Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

 Contact details:

Beylina N.I. — PhD (Medicine), Associate Professor, Department of Therapy, Geriatrics and Family Medical Care

Address: 36 Butlerov St., 420012 Kazan, tel.: +7-905-023-66-45, e-mail: nataliabeylina@mail.ru

The purpose — to evaluate the clinical manifestations of metabolic-associated fatty live disease (MAFLD) in primary care patients.

Material and methods. The study involved 22 men and 78 women with MAFLD examined on an outpatient basis. They underwent anamnesis assessment, anthropometry, determination of body mass index (BMI); ultrasound examination (ultrasound) of the liver; determination of cholesterol, glucose, and cytolysis markers (ALT, AST).

Results. Among the patients, 48.7% of women and 22.7% of men had elevated cholesterol levels (p > 0.05). Hyperglycemia was noted in 25.6% of women and 9.1% of men (p > 0.05). Mild cytolysis (up to 3 ALT norms) was recorded in 17.9% of women and 9.1% of men (p > 0.05) Hyperechoic liver was detected in 96% of women and 100% of men (p > 0.05), an increase in liver size in 43.6% and 59%, respectively (p > 0.05). Excess body weight/obesity was detected in 79.5% of women and 72.7% of men (p > 0.05). Among women, disorders of carbohydrate metabolism — DM2 and prediabetes — were detected more often than among men (34.6 and 9.1%, p < 0.05). The relationship between DM2 and obesity can be traced only in women. Excess body weight and obesity of various degrees were detected in 72.2% of women with DM2 and 88.9% of women with prediabetes (p > 0.05). The prevalence of hypertonic disease (HD) was found to be widespread among both men (86.4%) and women (66.7%) (p > 0.05). Coronary heart disease (CHD) was in the anamnesis of 3.8% of women and 22.7% of men (p < 0.05); 9.1% of men had suffered a myocardial infarction. As for concomitant diseases, cholelithiasis (CL) was found in 21.8% of women and 13.6% of men (p > 0.05).

Conclusion. Among patients with MAFLD, women predominate. Disorders of fat and carbohydrate metabolism and CL are more often detected in women and HD, CHD, GERD in men, which must be taken into account when diagnosing and correcting risk factors for MAFLD.

Key words: metabolic-associated fatty liver disease, obesity, diabetes mellitus.

REFERENCES

1. Tirikova O.V., Kozlova N.M., Kravchenko S.D. et al. Association of non-alcoholic fatty liver disease with cardiovascular pathology according to autopsy data. Eksperimental’naya i klinicheskaya gastroenterologiya, 2022, no. 7, pp. 38–44 (in Russ.).
2. Lazebnik L.B., Turkina S.V. NAFLD-associated comorbidity. Eksperimental’naya i klinicheskaya gastroenterologiya, 2021, no. 10, pp. 5–13 (in Russ.).
3. Devarbhavi H., Asrani S.K., Arab R. et al. Global burden of liver disease: 2023 update. J. Hepatol, 2023, vol. 79 (2), rr. 516–537.
4. Xing Y., Chen J., Liu J., Ma N. Associations between GGT/HDL and MaFLD: a cross-sectional study. Diabetes Metab. Syndr, 2022, no. 15, rr. 383–394.
5. Ivashkin V.T., Maevskaya M.V., Pavlov Ch.S. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2016, vol. 2, no. 26, pp. 24–42 (in Russ.).
6. Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology for the diagnosis and treatment of non-alcoholic fatty liver disease. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2022, vol. 4, no. 32, pp. 104–140 (in Russ.).
7. Evstifeeva S.E., Shal’nova S.A., Kutsenko V.A. et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE-RF-2 data (Epidemiology of cardiovascular diseases and their risk factors in the regions of the Russian Federation)). Kardiovaskulyarnaya terapiya i profilaktika, 2022, vol. 9, no. 21, p. 3356 (in Russ.).
8. Tsukanov V.V., Vasyutin A.V., Tonkikh Yu.L. New aspects of non-alcoholic fatty liver disease. Doktor.Ru, 2021, vol. 4, no. 20, pp. 33–39 (in Russ.).
9. Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol, 2020, vol. 73 (1), rr. 202–209.
10. Livzan M.A., Syrovenko M.I., Krolevets T.S. Non-alcoholic fatty liver disease and women’s health. RMZh. Meditsinskoe obozrenie, 2023, vol. 5, no. 7, pp. 310–317.
11. Maev I.V., Bakulin I.G., Bakulina N.V. et al. Clinical and endoscopic characteristics of GERD in patients with obesity. Effektivnaya farmakoterapiya, 2021, vol. 4, no. 17, pp. 12–20 (in Russ.).
12. Shestakova M.V., Shestakova E.A., Sklyanik I.A. et al. Obesity and diabetes mellitus — are they always together? Terapevticheskiy arkhiv, 2022, vol. 10, no. 94, pp. 1131–1135 (in Russ.).
13. Akhmedov V.A. Relationship between cardiovascular complications and non-alcoholic fatty liver disease. RMZh, 2018, vol. II, no. 1, pp. 86–88 (in Russ.).